title: Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
abstract: BACKGROUND
  Controlled oral challenge with nonsteroidal anti-inflammatory drugs (NSAIDs) is the only definite way to detect safe NSAIDs in patients with NSAID-induced anaphylactoid reactions.
  
  
  OBJECTIVE
  To evaluate the safety of the selective cyclooxygenase (COX) type 2 inhibitors rofecoxib and celecoxib in patients with single-reactive, NSAID-induced anaphylactoid reactions.
  
  
  METHODS
  We prospectively conducted single-blind, placebo-controlled oral challenges (SBPCOCs) with rofecoxib and celecoxib in 33 patients with single-reactive, NSAID-induced anaphylactoid reactions.
  
  
  RESULTS
  Nineteen women and 14 men (age range, 20-78 years; mean age, 44.8 years) exhibited anaphylactoid reactions on emergency department admission. Symptoms involved the skin (100%), laryngeal edema (73%), systolic hypotension (39%), and the gastrointestinal system (15%). The NSAIDs most frequently involved in the episodes were dipyrone (64%), propyphenazone (12%), and diclofenac (12%). In all patients, tolerance to a potent, nondiscriminatory COX inhibitor (except those reported as being responsible for the reaction) was noted. The SBPCOCs with the selective COX-2 inhibitors celecoxib and rofecoxib were well tolerated in all cases. Twenty-three patients who had an anaphylactoid reaction involving dipyrone and propyphenazone showed good tolerance to celecoxib (which contains a pyrazole group in its structure) on challenge.
  
  
  CONCLUSIONS
  The SBPCOCs with highly selective COX-2 inhibitors were safe in patients with single-reactive, NSAID-induced anaphylactoid reactions, even in cases that involved pyrazole derivatives.
authors.affiliation: Unidad de Alergia, Complejo Hospitalario de Jaén, Jaén, Spain. jqe01j@saludalia.com
authors.forename: Joaquin
authors.initials: J
authors.lastname: Quiralte
authors.forename: Julio
authors.initials: J
authors.lastname: Delgado
authors.forename: Blanca
authors.initials: B
authors.lastname: Sáenz de San Pedro
authors.forename: Esperanza
authors.initials: E
authors.lastname: López-Pascual
authors.forename: Maria Angustias
authors.initials: MA
authors.lastname: Nieto
authors.forename: Nancy
authors.initials: N
authors.lastname: Ortega
authors.forename: Jose Fernando
authors.initials: JF
authors.lastname: Florido
authors.forename: José
authors.initials: J
authors.lastname: Conde
mesh_terms: D000328:Adult; D000368:Aged; D000707:Anaphylaxis / Q000139:chemically induced*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000983:Antipyrine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004177:Dipyrone / Q000009:adverse effects; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011720:Pyrazoles; D016037:Single-Blind Method; D013449:Sulfonamides / Q000009:adverse effects*; D013450:Sulfones
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D004177:Dipyrone; D000068579:Celecoxib; C009077:propyphenazone; D000983:Antipyrine